April Kloxin, PhD, has received the 2019 National Institutes of Health (NIH) Director’s New Innovator Award to develop next-generation materials and tools to help accelerate research on idiopathic pulmonary fibrosis (IPF). Kloxin, a professor at the University of Delaware, is one of 60 researchers across the U.S. to win…
News
Scientists have found the mechanism by which a new mutation in the surfactant protein A1 (SFTPA1) gene leads to the onset and progression of idiopathic pulmonary fibrosis (IPF) in mice. Their findings were described in the study, “A homozygous SFTPA1 mutation drives necroptosis of type II alveolar…
A Japanese agency has cleared MediciNova’s request for a patent covering the use of its orally available candidates MN-001 (tipelukast) and MN-002 — a major metabolite of MN-001 — in treating idiopathic pulmonary fibrosis (IPF). The company announced it has received a Notice of Allowance from…
New research provides important insights into the process of activation and formation of cells that are crucial for fibrosis to occur, uncovering potential targets that can help control fibrosis in chronic diseases such as pulmonary fibrosis (PF). Scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) discovered…
Final data from the PRAISE trial support the efficacy and safety of pamrevlumab, an investigational therapy for the treatment of idiopathic pulmonary fibrosis (IPF) being developed by FibroGen. Data showed that into-the-vein (intravenous) infusions of pamrevlumab reduced the decline in respiratory function by 60.3%. It also cut to…
MN-001, a potential treatment for idiopathic pulmonary fibrosis (IPF), will soon have patent protections in China. MediciNova, the company developing MN-001 (tipelukast), received a Notice of Allowance from the Chinese Patent Office, which means that the company’s application fulfills all necessary requirements. Once issued, the patent is expected to…
The idiopathic pulmonary fibrosis (IPF) treatment candidate BBT-877 is safe and well-tolerated in healthy volunteers, and markedly reduced the plasma levels of a lipid molecule involved in inflammation and fibrosis, according to results of a Phase 1 clinical trial. The research, “BBT-877, a potent Autotaxin…
Ofev (nintedanib) reduced lung function decline by more than 50% in patients with progressive fibrosing interstitial lung diseases (ILDs), data from a Phase 3 trial show. The findings were presented in a poster at the recent European Respiratory Society (ERS) International Congress in Madrid, Spain, and simultaneously…
Blade Therapeutics will expand its pipeline in the field of fibrotic diseases with the acquisition of Atxco and its lead candidate PAT-409, which is ready to enter Phase 1 clinical studies. PAT-409 was engineered to specifically inhibit the autotaxin enzyme involved in the production of a fatty molecule called…
Blocking the activity of interleukin-11 (IL-11) — a molecule that mediates immune and inflammatory responses — reverses tissue scarring, or fibrosis, in the lungs of mice with idiopathic pulmonary fibrosis (IPF), a study has found. The findings of the study, “Interleukin-11 is a therapeutic target in idiopathic…
